Frankfurt
08.06.26 | 08:11
0,157 Euro
+0,77 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.05. | 2cureX AB: 2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor | 148 | GlobeNewswire (Europe) | 2cureX AB today announces the signing of a strategic services and collaboration agreement with StoreMyTumor, a US-based oncology logistics and tumour preservation platform operating under AAA Health... ► Artikel lesen | |
| 22.04. | 2cureX AB: 2cureX AB completes oversubscribed directed issue | 170 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") today announces that it has successfully completed an oversubscribed directed share issue of 6,800,000 shares to a select group of international investors (the... ► Artikel lesen | |
| 27.02. | 2cureX AB receives observation status | 223 | GlobeNewswire | Yesterday, February 26, 2026, 2cureX AB (the "Company") disclosed its annual financial statement release for 2025 with information on the Company's financial situation.
According to item 6.3.1... ► Artikel lesen | |
| 2CUREX Aktie jetzt für 0€ handeln | |||||
| 26.02. | 2cureX AB: 2cureX AB (publ) publishes Interim Report for the Second Half of 2025 | 168 | GlobeNewswire (Europe) | 2cureX AB ("2cureX" or the "Company") hereby publishes its interim report for the second half of 2025 (July 1 - December 31, 2025).
The second half of 2025 has been characterised by continued execution... ► Artikel lesen | |
| 21.08.25 | 2cureX AB: 2cureX AB (";2cureX") hereby publishes the interim report for the first half year of 2025. | 380 | GlobeNewswire (Europe) | The interim report is available as an attached document as well as on the company's website (https://www.2curex.se). A short summary of the report follows below.
CEO Nat Hutley comments:"EXECUTION.... ► Artikel lesen | |
| 01.07.25 | 2cureX AB: 2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG. | 325 | GlobeNewswire (Europe) | PreComb Therapeutics AG based in Switzerland and 2cureX AB have signed a Letter of Intent (LOI) to explore a strategic alliance that could align the scientific and commercial strengths of both companies... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,019 | -18,64 % | PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt | DJ PTA-Adhoc: Medigene AG: Widerruf der Zulassung der Aktien der Medigene AG zum Handel im regulierten Markt
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges... ► Artikel lesen | |
| EPIGENOMICS | 0,870 | 0,00 % | PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung | DJ PTA-HV: Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Hauptversammlung gemäß -- 121 Abs. 4a AktG
Epigenomics AG: Einladung zur ordentlichen Hauptversammlung
Heidelberg... ► Artikel lesen | |
| BIOFRONTERA | 2,520 | -2,33 % | BIOFRONTERA AG zeigt bemerkenswerte Stärke | ||
| NANOREPRO | 1,790 | -0,83 % | EQS-DD: NanoRepro AG: Lisa Jüngst, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
01.06.2026 / 09:43... ► Artikel lesen | |
| BIOXXMED | 0,800 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| OCUGEN | 1,136 | +1,79 % | Ocugen, Inc. - 8-K, Current Report | ||
| CLINUVEL | 5,408 | -1,85 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL US Non-Deal Roadshow Presentation | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,640 | +1,23 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| EDITAS MEDICINE | 2,310 | -1,70 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| SAREPTA THERAPEUTICS | 14,080 | +2,92 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| IBIO | 1,744 | +10,10 % | iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity | IBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety,... ► Artikel lesen | |
| ASEP MEDICAL | 0,100 | -100,00 % | CSE Bulletin: Suspensions - VSBLTY Groupe Technologies Corp., NuRAN Wireless Inc., GOAT Industries Ltd., BYT Holdings Ltd., ASEP Medical Holdings Inc., BioVaxys Technology Corp. | Le 6 mai/May 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading... ► Artikel lesen |
Das Unternehmen 2CUREX AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,001 (+0,77 %) liegt der Kurs bei 0,157 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 2CUREX AB finden Sie auf Wallstreet Online.